We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · September 02, 2021

Tau PET as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease

JAMA Neurology


Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Neurology
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging
JAMA Neurol 2021 Aug 01;78(8)961-971, R Ossenkoppele, R Smith, N Mattsson-Carlgren, C Groot, A Leuzy, O Strandberg, S Palmqvist, T Olsson, J Jögi, E Stormrud, H Cho, YH Ryu, JY Choi, AL Boxer, ML Gorno-Tempini, BL Miller, D Soleimani-Meigooni, L Iaccarino, R La Joie, S Baker, E Borroni, G Klein, MJ Pontecorvo, MD Devous, WJ Jagust, CH Lyoo, GD Rabinovici, O Hansson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading